Theralase Technologies introduces an innovative medical technology for bladder cancer treatment
Theralase® Technologies Inc. is a biopharmaceutical company with headquarters in Toronto, Canada.
The company focuses on the design, development, manufacturing, and sale of patented laser technology platforms. These platforms are useful for a wide range of bio-stimulative and bio-destructive clinical applications in patients.
Founded in 1994, Theralase has divided their operations into two divisions. The first one is therapeutic laser technology production for commercial applications. And the second is laser-based technology research and development to destruct cancer cells and other disease states.
Theralase® focuses on the development of laser-based non-invasive therapeutic devices. The company is focusing on these developments to eliminate pain, reduce inflammation, and accelerate tissue healing.
Their patented TLD-1433 photo dynamic compound has now successfully completed a Phase 1b Clinical Study for Non-Muscle Invasive Bladder Cancer (“NMIBC”).
For more information on Theralase Technologies Inc. (TLT:TSX.V, TLTFF:OTCQX) please fill out the form below.